[Featured Stock] BridgeBio, a 'Game Changer' Expected to Surpass 5 Trillion Won Sales of Ofev... "Focus on Potential for Lung Capacity Recovery"

BBT-877, Expected to Expand Indications with Potential Sales in the Trillion-Won Range

Bridge Biotherapeutics is showing strong performance. Expectations for the idiopathic pulmonary fibrosis (IPF) pipeline drug BBT-877 appear to be influencing the stock price.

As of 11:55 AM on the 3rd, Bridge Biotherapeutics is trading at 4,200 KRW, up 13.21% from the previous day.

Jae-kyung Park, a researcher at Hana Securities, explained, "We have completed the recruitment of 129 patients for the Phase 2 clinical trial of BBT-877," adding, "The trial is scheduled to be completed by April next year."

He continued, "Ofev (nintedanib) by Boehringer Ingelheim, a blockbuster drug for IPF, recorded sales of $3.8 billion last year," and added, "It is time to pay attention to the potential of BBT-877 as a second-generation treatment that can not only delay the decline in lung function like Ofev but also restore lung capacity."

Bridge Biotherapeutics stated that an internal analysis of the safety and efficacy data collected so far during the Phase 2 clinical trial of BBT-877 suggests that, in the best-case scenario, BBT-877 could be a 'game changer' capable of changing the existing paradigm.

They also noted that potential indications beyond idiopathic pulmonary fibrosis, based on unmet medical needs, could generate sales in the trillions of KRW range.